Recursion Pharmaceuticals
Recursion Pharmaceuticals raises $239M Series F at $4B valuation
Quick Facts
Recursion Pharmaceuticals: Series F Funding Round
Recursion Pharmaceuticals has successfully raised $239M in Series F funding, reaching a valuation of $4B.
Company Overview
AI-powered drug discovery
Funding Details
The Series F round was led by Baillie Gifford, with participation from ARK Investment Management, Mubadala Capital, Kinnevik, Catalio Capital Management.
Company Information
- Headquarters: 41 South Rio Grande Street, Salt Lake City, UT 84101
- Founded: 2013
- Employees: 500+
- Category: Biotech
Investment
Recursion Pharmaceuticals plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Baillie Gifford: Verified investor in Series F
- ARK Investment Management: Verified investor in Series F
- Mubadala Capital: Verified investor in Series F
- Kinnevik: Verified investor in Series F
- Catalio Capital Management: Verified investor in Series F
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...